Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
In 1977, 5-aminosalicylic acid (5-ASA) was discovered as a therapeutically active moiety of sulfasalazine (SASP) and was launched for topical and oral therapy of ulcerative colitis (UC) in 1984. As a first-step, delivery systems had to be developed to protect 5-ASA against absorption in the upper ga...
Main Authors: | Böhm, Stephan Karl, Kruis, Wolfgang |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181447/ |
Similar Items
-
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
by: Kruis, W, et al.
Published: (2009) -
Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
by: Takeshima, Fuminao, et al.
Published: (2014) -
Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
by: Matsumoto, Satohiro, et al.
Published: (2016) -
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
by: Oliveira, Lilliana, et al.
Published: (2011) -
Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
by: Park, Eun Hye, et al.
Published: (2012)